Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
BEFREE |
Here, we present a case of JMML with a KRAS G13D mutation.
|
24766281 |
2015 |
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
UNIPROT |
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
|
19075190 |
2009 |
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
|
3122217 |
1987 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
|
2278970 |
1990 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Implications of NRAS mutations in AML: a study of 2502 patients.
|
16434492 |
2006 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
|
22407852 |
2012 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
|
27358379 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This unique trial will yield prospective information on the efficacy of cetuximab and whether this is further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer: the "quadruple wild type", which may 'superselect' for tumours sensitive to EGFR-inhibition, and the rare KRAS G13D mutated tumours, which are also postulated to be sensitive to the drug.
|
27246726 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors.
|
26709701 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the G13D KRAS mutation normally predicts an intermediate outcome, the aggressive tumor behavior suggests other modifying factors in rare types of colonic carcinomas.
|
22180717 |
2011 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, a recent report suggested that the use of cetuximab was associated with survival benefit among patients with p.G13D-mutated tumors.
|
22043994 |
2012 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.
|
30896620 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether the efficacy of anti-EGFR mAbs for mCRC differs between tumours harbouring a KRAS G13D mutation (KRAS G13D) and KRAS mutations other than G13D (other KRAS MT).
|
26812186 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing.
|
24811330 |
2014 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, G12V mutations appeared to be associated with higher rates of tumor regression than G13D mutations (p=0.012).
|
19913317 |
2010 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Whereas, the KRAS mutation p.Gly13Asp have been detected only in MSI-H. 43.75 % of the patients harboured combined mutations in KRAS and TP53 genes and the tumor of 71.42 % of them showed TP53 overexpression.
|
24078161 |
2013 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far.
|
25367198 |
2014 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway.
|
30304546 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutations in primary tumors were identified in three regions; KARS (G13D) and APC (R876*) in P1-2, TP53 (A161S) in P1-3, and KRAS (G12D), PIK3CA (Q546R), and ERBB4 (T272A) in P1-4.
|
25623536 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with KRAS wild-type tumors have a longer progression-free survival (7.30 months [95% CI, 4.48-10.12 months]; HR 0.46 [95% CI, 0.23-0.91]; P = .025) and overall survival (19.0 months [95% CI, 10.2-27.8 months]; HR 0.32 [95% CI, 0.15-0.69]; P = .004) than patients with p.G13D-mutated tumors.
|
22537608 |
2012 |